Lung Cancer

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

January 28, 2021 - Although survivors and patients with lung cancer felt that they were involved in the treatment decision-making process, nearly half of them reported that they knew what their treatment options were before making a decision.

January 28, 2021 — Pembrolizumab in combination with chemotherapy continued to show improved overall survival and progression-free survival compared with chemotherapy alone in patients with previously untreated metastatic nonsquamous non–small cell lung cancer.

As new findings emerge in the lung cancer treatment paradigm, innovative strategies have resulted in impressive central nervous system activity and encouraging responses with acceptable tolerability.

Dan Costin, MD, discusses initial considerations in early-stage lung cancer.

Joshua K. Sabari, MD, discusses the role of concurrent plasma- and tissue-based molecular testing in lung cancer.

Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing research efforts in the space.

Naiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

January 26, 2021 - Novartis has signed a strategic collaboration agreement to in-license the PD-1 inhibitor tislelizumab from BeiGene, Ltd, in various markets outside of China.

Martin E. Gutierrez, MD, discusses some of the most encouraging ongoing clinical trials in metastatic NSCLC.

David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.

Henning Gaissert, MD, discusses the importance of tailoring surgical resection strategies to individual patients with lung cancer.

David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Expert discuss their expectations for research and drug development in oncology in the new year.

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.

Tony S.K. Mok, MD's, early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues.

Brendon Stiles, MD, discusses the roles of surgery, radiation, and chemotherapy in treatment for early-stage lung cancer.

Nicholas C. Rohs, MD, discusses the role of molecular testing in patients with lung cancer.

January 15, 2021 - Durvalumab has been approved in the European Union and the United Kingdom for a fixed-dose option of 1,500 mg every 4 weeks for use in patients with locally advanced, unresectable non–small cell lung cancer whose tumors have a PD-L1 expression of at least 1% and who have not experienced disease progression after platinum-based chemoradiation treatment.

Suresh S. Ramalingam, MD, FASCO, discusses the potential of HER2 as a driver mutation in non–small cell lung cancer.

David R. Gandara, MD, discusses the benefit of nivolumab and ipilimumab in combination with chemotherapy in metastatic non–small cell lung cancer.

Howard (Jack) West, MD, discusses the use of nivolumab in combination with ipilimumab in metastatic non–small cell lung cancer.

January 14, 2020 — The National Medical Products Administration of China has accepted a supplemental new drug application for sintilimab injection for use in the second-line treatment of patients with squamous non–small cell lung cancer.